News

News
June 22, 2021

Alchemab Therapeutics Appoints Douglas A. Treco, PhD as Chief Executive Officer

Industry Veteran Brings Experience and Proven Track Record of Success Plans for Management Team Expansion and Global Reach Through Newly Established U.S. Office Cambridge, UK and Boston, Massachusetts, June 22, 2021 – Alchemab Therapeutics, a biotechnology company focused on the discovery and development of naturally-occurring protective antibodies in neurodegeneration and oncology, today announced the appointment of […]

March 16, 2021

Alchemab and Medicines Discovery Catapult to develop landmark novel antibody therapy for Huntington’s disease

London, UK, 16 March 2021 – Alchemab, a biotech company developing novel therapeutics for patients with hard-to-treat diseases by harnessing the power of naturally protective antibodies, has been awarded a UK Biomedical Catalyst early award grant from Innovate UK to support the development of a novel disease-modifying antibody therapy for Huntington’s disease (HD). The grant will support Alchemab in its pioneering collaboration with Medicines Discovery Catapult.

November 5, 2020

Casting a spell: The Killer50 Magic Circle is unveiled

5 November 2020 – The operating landscape has changed remarkably for many life science and technology businesses in the Cambridge Cluster since the March 23 lockdown and subsequent restrictions affecting lifestyle and working practices. Read full article

November 1, 2020

Cambridge companies help develop Covid antibody cocktail

1 November 2020 – The UK BIA Antibody Taskforce, a UK consortium developing antibodies for treating COVID-19, has reached a major milestone – the identification of differentiated antibody combinations that will be taken forward for further development as an antibody cocktail. Read full article

October 29, 2020

Novel COVID-19 Antibody Therapy Candidates Identified by Leading UK Biotech Consortium

29 October 2020 – The UK BIA Antibody Taskforce, a leading UK consortium developing antibodies for treating COVID-19 has reached a major milestone – the identification of differentiated antibody combinations that will be taken forward for further development as an antibody “cocktail”. The Taskforce developed an accelerated and rigorous multifaceted approach to create a pool […]